Eli Lilly Bets $1.12 Billion on Gene Therapy for Hearing Loss in Strategic Biotech Deal
Amidst the blockbuster success of its weight-loss drugs, pharmaceutical giant Eli Lilly is making a strategic push into genetic medicine, securing exclusive rights to novel hearing loss treatments through a major partnership with German biotech Seamless Therapeutics.